
Feature|Articles|September 16, 2026
Cross-Functional Planning Is the Competitive Differentiator in CGT: Q&A with Chris Learn
Author(s)Chris Learn, PhD, MBA, PMP
CGT commercial trajectories are set years before approval — and every development decision is an access decision.
Advertisement
Advertisement
In June of this year, Pharmaceutical Executive published
Related to this article

Verismo Therapeutics licenses in vivo CAR T engineering technology from Stanford Medicine, while Pfizer licenses in vivo CAR-T programs from Starna Therapeutics.

Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its investigational antiviral obeldesivir.

FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.

Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
Advertisement
Advertisement


